natgillin/translations-raw huggingface dataset:
Patients weighing 50 kg had paclitaxel AUC approximately 25% lower than those weighing 75 kg. 
Bolniki, ki so tehtali 50 kg, so imeli AUC paklitaksela približno 25 % manjšo kot tisti, ki so tehtali 75 kg.
Use of filters with a pore size less than 15 µm may result in blockage of the filter. 
Uporaba filtrov s porami, manjšimi od 15 µm, lahko povzroči zamašitev filtra.
CNS metastases are generally not well controlled by systemic chemotherapy. 
Običajno metastaz CŽS ni mogoče dobro kontrolirati s sistemsko kemoterapijo.
Reduce subsequent dose only if criteria in Table 4 are met. 
Naslednji odmerek zmanjšajte le, če so izpolnjeni kriteriji iz preglednice 4.
Patient-reported taxane toxicity was assessed using the 4 subscales of the Functional Assessment of Cancer Therapy (FACT)-Taxane questionnaire. 
Toksičnost taksana, o kateri so poročali bolniki, so ocenjevali s 4 podlestvicami vprašalnika Funkcionalno ocenjevanje terapije raka (FACT)-taksan.
In addition, elimination of paclitaxel shows an inverse correlation with total bilirubin and a positive correlation with serum albumin. 
Poleg tega izločanje paklitaksela kaže obratno korelacijo s celokupnim bilirubinom in pozitivno korelacijo s serumskim albuminom.
Treatment was administered until disease progression or development of an unacceptable toxicity. 
Zdravljenje je trajalo do napredovanja bolezni ali razvoja nesprejemljive toksičnosti.
Unopened vials 2 years 
Neodprte viale 2 leti
Most of the individuals were previously exposed to cardiotoxic medicinal products such as anthracyclines, or had underlying cardiac history. 
Večina posameznikov je bila predhodno izpostavljena kardiotoksičnim zdravilom, na primer antraciklinom, ali je imela anamnezo srčne bolezni.
For the other subscale (oedema), there was no difference in the treatment arms. 
Pri preostali podlestvici (edemi) ni bilo razlik med skupinami zdravljenja.
A non-inferiority analysis was conducted for PFS and OS, with a pre-specified non-inferiority margin of 15%. 
Opravili so analizo neinferiornosti za PFS in OS ob vnaprej določeni meji neinferiornosti 15 %.
• Breast cancer which has spread to other parts of the body (this is called “metastatic” breast cancer). 
• Rak dojk, ki se je razširil v druge dele telesa (to se imenuje »metastatski« rak dojk).
Limiting the infusion of Pazenir to 30 minutes, as directed, reduces the likelihood of infusion-related reactions. 
Omejitev infundiranja zdravila Pazenir na 30 minut, kot je navedeno v navodilih, zmanjša možnost z infuzijo povezanih reakcij.
Patients with high cardiovascular risk, history of peripheral artery disease and/or of connective tissue disorders and/or interstitial lung disease were excluded from the study. 
Bolniki z velikim kardiovaskularnim tveganjem, anamnezo bolezni perifernih arterij in/ali boleznimi veziva in/ali intersticijsko boleznijo pljuč so bili izključeni iz študije.
Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in viali poleg oznake »EXP«.
This medicine has not been studied in children and adolescents, as breast cancer, pancreatic cancer and lung cancer do not occur in these age groups. 
Tega zdravila pri otrocih in mladostnikih niso preučili, saj se v teh starostnih skupinah rak dojk, rak trebušne slinavke in pljučni rak ne pojavljajo.
In the event of an overdose, the patient should be closely monitored. 
V primeru prevelikega odmerka mora biti bolnik pod strogim nadzorom.
*This data is based on Clinical Study Report: CA012-0 Addendum dated Final (23 March-2005) a Chi-squared test b Log-rank test 
*Ti podatki temeljijo na poročilu klinične študije: CA012-0 Dodatek datiran kot zadnji (23. marec 2005) a Hi-kvadrat test b Log-rank test
Overall Response Rate 
Stopnja celokupnega odziva
Febrile Neutropenia: 
Febrilna nevtropenija:
• Deficiency of red blood cells 
• pomanjkanje rdečih krvnih celic
The primary efficacy endpoint was overall response rate defined as the percentage of patients who achieved an objective confirmed complete response or partial response based on an independent, central, blinded radiological review using RECIST (Version 1.0). 
Primarni cilj študije je bil stopnja celokupnega odziva, opredeljena kot odstotni delež bolnikov, ki so dosegli objektiven potrjen popoln odziv ali delen odziv na podlagi neodvisnega, centralnega, slepega radiološkega pregleda po smernicah RECIST (različica 1.0).
• Difficulty in breathing 
• težave pri dihanju
Confirmed complete or partial overall response, n (%) 
Potrjen popoln ali delen celokupni odziv, n (%)
Figure 1: Kaplan-Meier curve of overall survival (intent-to-treat population) 
Slika 1: Kaplan-Meierjeva krivulja celokupnega preživetja (populacija z namenom zdravljenja)
Treat with same dose 
Zdravite z enakim odmerkom
• Painful urination, frequent urination, blood in the urine, inability to hold your urine 
• boleče uriniranje, pogosto uriniranje, kri v urinu, nezmožnost zadrževanja urina
Then, the vial should gently and slowly be swirled and/or inverted for at least 2 minutes until complete redispersion of any powder occurs. 
Nato vialo pazljivo in počasi sučite in/ali obračajte vsaj 2 minuti, dokler se ves prašek popolnoma ne redispergira.
Gloves, goggles and protective clothing should be used. 
Uporabljati je treba rokavice, zaščitna očala in zaščitne obleke.
• Ear pain, ringing in your ears 
• bolečine v ušesih, zvonjenje v ušesih
This stability results in the inhibition of the normal dynamic reorganisation of the microtubule network that is essential for vital interphase and mitotic cellular functions. 
Stabilizacija mikrotubulov zavira normalno dinamično reorganizacijo mikrotubularne mreže, ki je nujna za življenjsko pomembne celične funkcije v interfazi in mitozi.
Paclitaxel has minor or moderate influence on the ability to drive and use machines. 
Paklitaksel ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja strojev.
Pazenir is for intravenous use. 
Zdravilo Pazenir je za intravensko uporabo.
The non-inferiority criterion was met for both PFS and OS with the upper bound of the 95% confidence interval for the associated hazard ratios being less than 1.176 (Table 13). 
Kriterij neinferiornosti je bil izpolnjen tako za PFS kot za OS z zgornjo mejo 95-odstotnega intervala zaupanja za pridruženi razmerji tveganja, ki sta bili manjši od 1,176 (Preglednica 13).
The reconstituted dispersion has a pH of 6-7.5 and an osmolality of 300-360 mOsm/kg. 
Rekonstituirana disperzija ima pH vrednost 6-7,5 in osmolalnost 300-360 mOsm/kg.
Some settling of the reconstituted dispersion may occur. 
Lahko se pojavi manjše usedanje rekonstituirane disperzije.
Very rare: Stevens-Johnson syndrome2, toxic epidermal necrolysis2 
Zelo redki: Stevens-Johnsonov sindrom2, toksična epidermalna nekroliza2
Neutropenia is dose-dependent and a dose-limiting toxicity. 
Nevtropenija predstavlja od odmerka odvisno in odmerek omejujočo toksičnost.
• Albumin is the part of the medicine that helps paclitaxel dissolve in the blood and get across the walls of the blood vessels into the tumour. 
• Albumin je del zdravila, ki pomaga paklitakselu, da se raztopi v krvi in prehaja skozi stene krvnih žil v tumor.
Following intravenous administration of radiolabelled paclitaxel to rats on days 9 to 10 postpartum, concentrations of radioactivity in milk were higher than in plasma and declined in parallel with the plasma concentrations. 
Po intravenskem dajanju radioaktivno označenega paklitaksela podganam na 9. in 10. dan po kotitvi so bile koncentracije radioaktivnosti v mleku večje kot v plazmi in so se zmanjševale hkrati s koncentracijami v plazmi.
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na vialo, kar v bistvu pomeni ‘brez natrija'.
Pregnant staff should not handle Pazenir. 
Noseče osebje ne sme rokovati z zdravilom Pazenir.
Following recurrence of severe neutropenia or severe sensory neuropathy, additional dose reduction should be made to 180 mg/m2. 
Ob ponovitvi hude nevtropenije ali hude senzorične nevropatije je treba odmerek dodatno zmanjšati na 180 mg/m2.
Treat with same doses as patients with normal hepatic function. 
Zdravite jih z enakimi odmerki kot bolnike z normalnim delovanjem jeter.
• medicines for treating infections (i.e. antibiotics such erythromycin, rifampicin, etc.; ask your doctor, nurse or pharmacist if you are unsure whether the medicine you are taking is an antibiotic), and including medicines for treating fungal infections (e.g. ketoconazole) 
• zdravila za zdravljenje okužb (tj. antibiotiki, kot so eritromicin, rifampicin itd.; posvetujte se z zdravnikom, medicinsko sestro ali farmacevtom, če niste prepričani, ali je zdravilo, ki ga jemljete, antibiotik), in tudi zdravila za zdravljenje glivičnih bolezni (npr. ketokonazol)
Neither freezing nor refrigeration adversely affects the stability of the product. 
Na stabilnost zdravila ne vpliva niti zamrzovanje niti hlajenje.
Table 10: Results for overall response rate, median time to disease progression, and progression-free survival as assessed by the investigator 
Preglednica 10: Rezultati stopenj celokupnega odziva, mediane časa do napredovanja bolezni in preživetja brez napredovanja bolezni, kot jih je ocenil raziskovalec
Post-marketing experience 
Izkušnje po začetku trženja
Pharmacokinetic data are insufficient for patients with severe renal impairment and not available for patients with end stage kidney disease. 
Farmakokinetični podatki so nezadostni pri bolnikih s hudo okvaro ledvic in niso na voljo pri bolnikih s končno ledvično odpovedjo.
16% had a Karnofsky Performance Status of 100; 42% had a KPS of 90; 35% had a KPS of 80; 7% had a KPS of 70; and <1% of patients had a KPS of below 70. 
16 % jih je imelo oceno stanja zmogljivosti po Karnofskem (KPS) 100; 42 % jih je imelo KPS 90; 35 % jih je imelo KPS 80; 7 % jih je imelo KPS 70 in < 1 % bolnikov pa je imelo KPS manjše od 70.
If a patient becomes febrile (regardless of neutrophil count), initiate treatment with broad spectrum antibiotics. 
Če bolnik postane febrilen (ne glede na število nevtrofilcev), začnite zdravljenje s širokospektralnimi antibiotiki.
Each medicinal product was administered on Day 1 of each 21-day cycle. 
Vsako zdravilo so dali 1. dan vsakega 21-dnevnega cikla.
Rare occurrences of severe hypersensitivity reactions, including very rare events of anaphylactic reactions with fatal outcome, have been reported. 
Poročali so o redkih pojavih hudih preobčutljivostnih reakcij, vključno z zelo redkimi dogodki anafilaktičnih reakcij s smrtnim izidom.
• Increased bilirubin in the blood 
• zvišan bilirubin v krvi
Do not breast feed when taking Pazenir as it is not known if the active ingredient paclitaxel passes into the mother's milk. 
Med jemanjem zdravila Pazenir ne smete dojiti, saj ni znano, ali učinkovina paklitaksel prehaja v materino mleko.
On Days 8 or 15 of the 21-day cycle reduce the dose of Pazenir; reduce the dose of carboplatin in the subsequent cycle. 
8. ali 15. dan 21-dnevnega cikla zmanjšajte odmerek zdravila Pazenir; odmerek karboplatina zmanjšajte v naslednjem ciklu.
If a hypersensitivity reaction occurs, the medicinal product should be discontinued immediately, symptomatic treatment should be initiated, and the patient should not be rechallenged with paclitaxel. 
Če se pojavi preobčutljivostna reakcija, je treba takoj ukiniti uporabo zdravila; uvesti je treba simptomatsko zdravljenje, bolniku pa se paklitaksela ne sme ponovno dati.
• if you have severe liver problems; 
• če imate hude težave z jetri;
The reduced dose may be escalated to the dose for patients with normal hepatic function if the patient is tolerating the treatment for at least two cycles (see sections 4.4 and 5.2). 
Zmanjšani odmerek lahko spet zvečate na odmerek za bolnike z normalnim delovanjem jeter, če bolnik prenaša zdravljenje vsaj dva cikla (glejte poglavji 4.4 in 5.2).
For patients of 75 years and older, no benefit for the combination treatment of Pazenir and gemcitabine in comparison to gemcitabine monotherapy has been demonstrated. 
Pri bolnikih, starih 75 let in več, niso dokazali nikakršne koristi kombiniranega zdravljenja z zdravilom Pazenir in gemcitabinom v primerjavi z monoterapijo z gemcitabinom.
If you are given other medicines as part of your treatment, you should ask your doctor for advice on driving and using machines. 
Če jemljete druga zdravila v okviru zdravljenja, se z zdravnikom posvetujte o upravljanju vozil in strojev.
Closely monitor all patients for signs and symptoms of pneumonitis. 
Skrbno spremljajte vse bolnike glede znakov in simptomov pnevmonitisa.
Patients with pre-existing neuropathy of Grade ≥ 2 or serious medical risk factors involving any of the major organ systems were excluded. 
nevropatijo ≥ 2. stopnje ali resnimi medicinskimi dejavniki tveganja v zvezi s katerim koli pomembnim organskim sistemom so izključili.
• Leaking of drug outside the vein 
• iztekanje zdravila zunaj vene
Lymphopenia was observed in 45% of the patients. 
Limfopenija se je pojavila pri 45 % bolnikov.
Paclitaxel may cause adverse reactions such as tiredness (very common) and dizziness (common) that may affect the ability to drive and use machinery. 
Paklitaksel lahko povzroča neželene učinke, kot je utrujenost (zelo pogosto) in omotičnost (pogosto), ki lahko vplivajo na sposobnost upravljanja vozil in strojev.
Paclitaxel and/or its metabolites were excreted into the milk of lactating rats. 
Paklitaksel in/ali njegovi presnovki so se izločali v mleko doječih podgan.
What you need to know before you use Pazenir Do not use Pazenir 
Kaj morate vedeti, preden boste prejeli zdravilo Pazenir Ne uporabljajte zdravila Pazenir
1 Year 
1 letu
Complications due to the underlying pancreatic cancer, especially biliary obstruction or presence of biliary stent, were identified as significant contributing factors. 
Zaplete zaradi osnovne bolezni, raka trebušne slinavke, zlasti biliarno obstrukcijo ali prisotnost biliarnega stenta, so prepoznali kot pomembne dejavnike, ki prispevajo k nastanku sepse.
Stability of reconstituted dispersion in the vial 
Stabilnost rekonstituirane disperzije v viali
The response rates in all patients were 39.5% (95% CI: 24.9%54.2%) and 47.6% (95% CI: 35.3%-60.0%), respectively. 
Stopnji odzivnosti pri vseh bolnikih sta bili 39,5 % (95-% IZ: 24,9 % - 54,2 %) oziroma 47,6 % (95-% IZ: 35,3 % - 60,0 %).
The primary efficacy endpoint was overall survival (OS). 
Primarni cilj študije za dokaz učinkovitosti je bilo celokupno preživetje (OS - overall survival).
a Per EMA methodological considerations for PFS endpoint, missing observations or initiation of subsequent new therapy were not used for censoring. 
a Na podlagi metodoloških premislekov EMA za PFS, manjkajoča opazovanja ali uvedba poznejšega novega zdravljenja niso bili uporabljeni kot delno znani podatki.
Contents of the pack and other information What Pazenir contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Pazenir
The paclitaxel exposure (AUC) increased linearly from 2653 to 16736 ng.hr/ml following dosing from 80 to 300 mg/m2. 
Izpostavljenost paklitakselu (AUC) je naraščala linearno od 2.653 na 16.736 ng.hr/ml, po odmerjanju od 80 do 300 mg/m2.
The median time to disease progression was 5.3 months (175 mg/m2; 95% CI: 4.6-6.2 months) and 6.1 months (300 mg/m2; 95% CI: 4.2-9.8 months). 
Mediani čas do napredovanja bolezni je bil 5,3 meseca (175 mg/m2; 95-% IZ: 4,6 - 6,2 meseca) in 6,1 meseca (300 mg/m2; 95-% IZ: 4,2 - 9,8 meseca).
It is not known if paclitaxel is excreted in human milk. 
Ni znano, ali se paklitaksel izloča v materino mleko.
Do not administer the reconstituted dispersion if particulate matter is observed in the vial. 
Ne uporabite rekonstituirane disperzije, če v viali opazite vidne delce.
In addition, paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. 
Paklitaksel prav tako povzroča nenormalne skupke ali »svežnje« mikrotubulov tekom celotnega celičnega ciklusa in večkratne astere mikrotubulov med mitozo.
Monitor patients closely for signs and symptoms of pneumonitis. 
Skrbno spremljajte bolnike glede znakov in simptomov pnevmonitisa.
• Pazenir is also used together with a medicine called carboplatin if you have the most common type of lung cancer, called “non-small cell lung cancer”. 
• Zdravilo Pazenir se uporablja tudi skupaj z zdravilom, ki se imenuje karboplatin, če imate najpogostejšo vrsto pljučnega raka, imenovano “nedrobnocelični pljučni rak”.
Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during administration of the medicinal product. 
Zaradi možnosti ekstravazacije se priporoča skrbno nadziranje mesta infundiranja zaradi možnosti infiltracije med dajanjem zdravila.
• Effect on peripheral nerves (pain, numbness, tingling or loss of feeling) 
• učinki na periferno živčevje (bolečine, odrevenelost, mravljinčenje ali izguba občutkov)
Once the addition is complete, the vial should be allowed to stand for a minimum of 5 minutes to ensure proper wetting of the solid. 
Ko je dodajanje končano, naj viala stoji najmanj 5 minut, da se bo trdna snov primerno omočila.
Reconstituted dispersion For storage conditions after reconstitution of the medicinal product, see section 6.3. 
Rekonstituirana disperzija Za pogoje shranjevanja po rekonstituciji zdravila glejte poglavje 6.3.
Also, some other medicines can affect the way Pazenir works. 
Tudi druga zdravila lahko vplivajo na način delovanja zdravila Pazenir.
Pharmacokinetic interactions between Pazenir and gemcitabine have not been evaluated in humans. 
Farmakokinetičnega medsebojnega delovanja med zdravilom Pazenir in gemcitabinom pri ljudeh niso proučevali.
Instructions for use, handling and disposal Preparation and administration precautions 
Navodila za uporabo, ravnanje in odstranjevanje Previdnostni ukrepi pri pripravi in dajanju zdravila
This is because Pazenir can affect the way some other medicines work. 
Zdravilo Pazenir lahko namreč vpliva na način delovanja drugih zdravil.
Treatment may be resumed at the next lower dose level in subsequent cycles according to the guidelines in Table 5. 
V poznejših ciklih se lahko zdravljenje nadaljujte z naslednjo nižjo ravnijo odmerka v skladu s smernicami v preglednici 2.
The median time to improvement by at least 1 grade was 21 days, and the median time to improvement from Grade 3 peripheral neuropathy to Grade 0 or 1 was 29 days. 
Mediani čas do izboljšanja za vsaj eno stopnjo je bil 21 dni, mediani čas do izboljšanja s periferne nevropatije 3. stopnje na 0. ali 1. stopnjo pa je bil 29 dni.
Myelosuppression events, peripheral neuropathy events, and arthralgia were more frequent in patients 65 years or older compared to patients younger than 65 years of age. 
Neželeni dogodki, kot so mielosupresija, periferna nevropatija in artralgija, so bili pogostejši pri bolnikih, starih 65 let ali več, kot pri bolnikih, mlajših od 65 let.
• Changes in heart rate or rhythm, heart failure 
• spremembe srčnega utripa ali ritma, popuščanje srca
Other medicines and Pazenir 
Druga zdravila in zdravilo Pazenir
Patients received a median of 6 cycles of treatment in both study arms. 
Mediano število ciklov zdravljenja, ki so jih bolniki prejeli v obeh skupinah študije, je bilo 6.
The natural course of peripheral neuropathy to resolution to baseline due to cumulative toxicity of human serum albumin-paclitaxel nanoparticles after > 6 courses of treatment was not evaluated and remains unknown. 
Naravni potek periferne nevropatije do resolucije na izhodiščno raven zaradi kumulativne toksičnosti paklitaksela, vezanega na nanodelce humanega serumskega albumina, po > 6 zdravljenjih ni bil raziskan in ostaja neznan.
• if you have poor kidney function; 
• če imate zmanjšano delovanje ledvic;
There is no known antidote for paclitaxel overdose. 
Ni znanega protistrupa za prevelik odmerek paklitaksela.
• a medicine called clopidogrel used to prevent blood clots 
• zdravilo, ki se imenuje klopidogrel in se uporablja za preprečevanje krvnih strdkov.
Pazenir should not be used in combination with other anticancer agents. 
Zdravilo Pazenir se ne sme uporabljati v kombinaciji z drugimi zdravili proti raku.
Withhold doses until improves to ≤ Grade 1; 
Prekinite dajanje odmerkov, dokler se ne izboljša na ≤ 1. stopnjio;
Gastrointestinal disorders Nausea occurred in 29% of the patients and diarrhoea in 25% of the patients. 
Bolezni prebavil Navzea se je pojavila pri 29 % bolnikov, diareja pa pri 25 % bolnikov.
• medicines used to help you stabilize your mood also sometimes referred to as anti-depressants (e.g. fluoxetine) 
• zdravila, ki se uporabljajo za stabilizacijo razpoloženja, imenovani tudi antidepresivi (npr. fluoksetin)
What Pazenir is and what it is used for What you need to know before you are given Pazenir How to use Pazenir 
Kaj je zdravilo Pazenir in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Pazenir Kako uporabljati zdravilo Pazenir
Nadir ANC <500/mm3 with neutropenic fever > 38°C 
najmanjše ANC < 500/mm3 z vročino zaradi nevtropenije > 38 °C
If precipitates or settling are visible, the vial should be gently inverted again to ensure complete redispersion prior to use. 
Če pride do tvorbe oborin ali usedanja, vialo ponovno pazljivo obračajte navzgor in navzdol, da boste zagotovili popolno redispergiranje pred uporabo.
When counts recover, resume dosing the following week according to the criteria in Table 4. 
Ko se število celic obnovi, naslednji teden nadaljujte odmerjanje v skladu s kriteriji iz preglednice 4.
Pazenir should not be used in pregnancy, and in women of childbearing potential not using effective contraception, unless the clinical condition of the mother requires treatment with paclitaxel. 
Zdravila Pazenir ne smete uporabljati pri nosečnicah in ženskah v rodni dobi, ki ne uporabljajo zanesljive kontracepcije, razen če klinično stanje nosečnice zahteva zdravljenje s paklitakselom.
After first reconstitution the dispersion should be used immediately. 
Po prvi rekonstituciji morate disperzijo uporabiti takoj.
It is hypothesised that this enhanced transendothelial caveolar transport is mediated by the gp-60 albumin receptor, and that there is enhanced accumulation of paclitaxel in the area of tumour due to the albumin-binding protein Secreted Protein Acidic Rich in Cysteine (SPARC). 
Obstaja hipoteza, da ta izboljšani transendotelijski kaveolarni transport posreduje albuminski receptor gp-60, in da izboljšano akumulacijo paklitaksela v območju tumorja povzroča izločena, albumin-vezajoča beljakovina, kisla, bogata s cisteinom (SPARC - Secreted Protein Acidic Rich in
• Severe inflammation/eruption of the skin and mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) 
• hudo vnetje/izbruh izpuščajev na koži in sluznici (Stevens-Johnsonov sindrom, toksična epidermalna nekroliza)
For treatment of metastatic breast cancer, Pazenir is usually given once every three weeks (on day 1 of a 21-day cycle). 
Pri metastatskem raku dojk se zdravilo Pazenir navadno daje enkrat na tri tedne (1. dan 21-dnevnega cikla).
Albumin is known to mediate endothelial caveolar transcytosis of plasma constituents, and in vitro studies demonstrated that the presence of albumin enhances transport of paclitaxel across endothelial cells. 
Znano je, da albumin posreduje endotelijsko kaveolarno transcitozo sestavin plazme; in vitro raziskave pa so pokazale, da prisotnost albumina izboljša transport paklitaksela preko endotelijskih celic.
• Pain and swelling in the nose, skin infections, infection due to catheter line 
• bolečine in otekline v nosu, kožna okužba, okužba zaradi katetra
Your doctor will arrange a pregnancy test before starting treatment with Pazenir. 
Zdravnik bo uredil, da boste pred začetkom zdravljenja z zdravilom Pazenir opravili test nosečnosti.
After first reconstitution, the dispersion should be filled into an infusion bag immediately. 
Po prvi rekonstituciji je treba disperzijo takoj napolniti v infuzijsko vrečo.